Biotech News
GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
GSK today announced that data across the oncology pipeline and portfolio will be presented at ASCO and EHA.
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-21 10:28 EST
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026
BCRXBioCryst Pharmaceuticals2026-06-29 11:00 EST
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
REGNRegeneron Pharmaceuticals2026-07-31 11:00 EST
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
SNDXSyndax Pharmaceuticals2026-06-11 11:00 EST
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Stock data
- Close
- 52.17 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States